TempraMed Technologies Ltd. (CSE:VIVI)
Canada · Delayed Price · Currency is CAD | Market Cap | 25.63M -61.6% |
| Revenue | n/a |
| Net Income | n/a |
| EPS | n/a |
| Shares Out | 77.67M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 75,400 |
| Open | 0.4000 |
| Previous Close | 0.4200 |
| Day's Range | 0.2400 - 0.4000 |
| 52-Week Range | 0.2700 - 1.4000 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About TempraMed Technologies
TempraMed Technologies Ltd., a medical device technology company, develops patent-protected technology designed to serve a broad range of medical and consumer products. Its primary focus is storage and management of injectable for temperature-sensitive medications. The company provides VIVI Cap, an insulin insulation and travel case; VIVI Cap Smart, a connected insulin storage and protection; VIVI Med, a temperature medication; and VIVI Epi, a Storage and Protection for EpiPen. The company was incorporated in 2023 and is based in Burnaby, Canad... [Read more]
News
TempraMed Signs Exclusive Distribution Agreement with SPORTORO for Croatia, Serbia and Bosnia and Herzegovina
Three-country commercial framework value of approximately US$550,000 over its initial three-year term based on VIVI Cap pricing at the scheduled minimum unit volumes Highlights Definitive exclusive di...
TempraMed Announces LIFE Offering up to C$8 Million to Accelerate Global Expansion and Fulfilment of Forecasted Demand
Strategic financing to scale the growth of the Company, increase global distribution and fulfill strong pipeline of new distribution agreements and B2B contracts Recent Highlights: Record sales: July ...
TempraMed Enters into Exclusive Kuwait Distribution Agreement, Expanding Gulf Region Commercial Footprint
Represents approximately US$500,000 in potential minimum purchases over the initial term and targets growing demand for medication temperature protection across insulin, GLP-1 therapies, biologics and...
TempraMed Granted Mexican Patent for Newest Product, VIVI Box
Grant in Mexico marks a major milestone in global IP strategy, advancing protection of its VIVI Box platform across key international markets Highlights Covers core innovations underpinning TempraMed'...
TempraMed Announces VIVI Cap Smart Connectivity with Apple Health and Google Fit, Providing Better Health Outcomes and Data Tracking
VIVI Cap Smart transforms injectable medication protection into a connected health-data layer, enabling patients, caregivers and digital-health platforms to capture medication-use, temperature and adh...
TempraMed Technologies Ltd. Announces Closing of Private Placement
Toronto, Ontario--(Newsfile Corp. - September 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company"), is pleased to announce that, further to its September 23, 2026 and Sep...
TempraMed Signs Letter of Intent with CPO Cyprus for Exclusive Distribution of VIVI Products in Cyprus
Distribution partnership with one of Cyprus's most established healthcare and consumer-products distributors Highlights: LOI with CPO Cyprus includes exclusive distribution of VIVI Cap™ and VIVI Epi™ ...
TempraMed Announces Upsize to Offering
Toronto, Ontario--(Newsfile Corp. - September 28, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company") is pleased to announce an upsize (the "Upsized Offering") to the non-br...
TempraMed Expands Latin American Distribution Agreement with TEM and Receives Additional Commercial Order, Announces Private Placement
Amendment extends TEM relationship beyond Panama into additional Latin American markets, adds VIVI Med(TM) to the distribution framework, and supports broader regional availability following product r...
TempraMed Announces Distribution Agreement with CenterWell Pharmacy(R), the Pharmacy Services Brand of Humana
Toronto, Ontario--(Newsfile Corp. - September 23, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (OTCQB: TMPTF) ("TempraMed" or the "Company"), a medical-technology innovator transforming ...
TempraMed Reports Record July Sales and Strong August Performance, with Year-to-Date Sales Already Exceeding Full-Year 2025 Revenue
Company reports US$522K in July sales, US$403K in August sales, and US$2.07M in sales for the first eight months of 2026, surpassing US$1.8M in total sales for 2025 Toronto, Ontario--(Newsfile Corp. -...
TempraMed Signs Letter of Intent with CPO Greece for Exclusive Distribution of VIVI Products in Greece
Distribution framework pairs TempraMed's injectable medication-protection products with one of the largest, most established Greek pharmacy and healthcare distributors Highlights: LOI with CPO Greece ...
TempraMed Signs Definitive Five-Year Saudi Arabia Distribution Agreement for Private-Label VIVI Cap
Agreement targets commercialization through the physical retail network of Nahdi Medical Company, Saudi Arabia's largest pharmacy chain. Highlights Five-year definitive agreement with approximately US...
TempraMed Announces Extension of Maccabi Healthcare Services Agreement
Maccabi exercises option to extend agreement for an additional year, reinforcing continued adoption of TempraMed's medication protection technology Toronto, Ontario--(Newsfile Corp. - August 20, 2026)...
TempraMed Executes Definitive Exclusive Distribution Agreement with TEM in Panama, Advancing Commercial Expansion Across Clinics and Pharmacies
Agreement transitions previously announced LOI into a definitive commercial relationship First bulk commercial order fulfilled for distribution into clinics and pharmacies TempraMed expands access to ...
TempraMed Uplists to OTCQB Venture Market and Achieves DTC Eligibility, Expanding Access to U.S. Investors
Toronto, Ontario--(Newsfile Corp. - July 30, 2026) - TempraMed Technologies Ltd. (CSE: VIVI) (OTCQB: TMPTF) (FSE: 9DY) ("TempraMed" or the "Company") is pleased to announce that its common shares have...